title: Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.
abstract: Previous studies regarding the association of p53 codon 72 Arg/Pro polymorphism with hepatocellular carcinoma (HCC) risk have provided conflicting and inconclusive findings. Thus, a meta-analysis of all currently available publications was performed to address this issue. Eleven individual case-control studies involving a total of 2,718 cases and 3,752 controls were identified after a systematic search of the PubMed, Embase, Web of Science, and Wanfang databases. The strength of the association of p53 codon 72 Arg/Pro polymorphism with HCC risk was estimated by the pooled odds ratio (OR) with its corresponding 95 % confidence interval (95 % CI). Subgroup analyses stratified by ethnicity, source of controls, gender, hepatitis virus infection status, and family history of HCC were also conducted to assess the association. Overall, significantly increased risk of HCC was identified among carriers of the homozygous genotype ProPro (ORProPro vs. ArgArg=1.38 (95 % CI, 1.03-1.85), P OR=0.033; ORProPro vs. ArgArg + ArgPro =1.28 (95 % CI, 1.03-1.59), P OR=0.026). In subgroup analysis by ethnicity, the pooled results suggested that the p53 codon 72 Arg/Pro polymorphism was associated with an increased risk of HCC in Asians and Caucasians (for Asians, ORProPro vs. ArgArg + ArgPro=1.17 (95 % CI, 1.02-1.34), P OR=0.025; for Caucasians, ORProPro vs. ArgArg = 1.65 (95 % CI, 1.07-2.56), P OR=0.025; ORProPro vs. ArgArg + ArgPro=1.74 (95 % CI, 1.14-2.66), P OR=0.010). Subgroup analyses by source of controls and hepatitis virus infection status further demonstrated the significant association, whereas stratification factors involving gender and family history of HCC did not modify the association between p53 codon 72 Arg/Pro polymorphism and HCC risk. This meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism may play a critical role in the development of HCC, and gender and family history of HCC may not modulate the effect of p53 codon 72 Arg/Pro in HCC risk.
authors.affiliation: Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.
authors.forename: Long
authors.initials: L
authors.lastname: Lv
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Zhou
authors.forename: Beicheng
authors.initials: B
authors.lastname: Sun
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000209:etiology*; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology*; D011110:Polymorphism, Genetic / Q000235:genetics*; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
references.citation: Int J Cancer. 2007 Oct 1;121(7):1481-6
references.pmid: 17546594
references.citation: Liver Int. 2005 Apr;25(2):220-5
references.pmid: 15780042
references.citation: Int J Mol Med. 2000 Apr;5(4):405-9
references.pmid: 10719058
references.citation: Curr Oncol Rep. 2004 May;6(3):177-83
references.pmid: 15066228
references.citation: Nat Rev Cancer. 2006 Sep;6(9):674-87
references.pmid: 16929323
references.citation: Cancer Lett. 2009 Dec 1;286(1):52-9
references.pmid: 19147276
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Lancet Oncol. 2009 Sep;10(9):913-9
references.pmid: 19717093
references.citation: Infect Agent Cancer. 2011 Aug 15;6:13
references.pmid: 21843334
references.citation: Hepatol Res. 2007 Sep;37(9):748-54
references.pmid: 17573955
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Carcinogenesis. 2008 Jun;29(6):1192-6
references.pmid: 18390844
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Tumour Biol. 2012 Aug;33(4):927-33
references.pmid: 22249977
references.citation: Expert Rev Anticancer Ther. 2001 Aug;1(2):277-90
references.pmid: 12113033
references.citation: Cancer Lett. 2014 Jan 28;342(2):223-30
references.pmid: 22306342
references.citation: Hepatology. 1999 Mar;29(3):697-702
references.pmid: 10051470
references.citation: Cancer Lett. 2005 Nov 8;229(1):77-83
references.pmid: 15979781
references.citation: Science. 1993 Dec 24;262(5142):1980-1
references.pmid: 8266092
references.citation: Dis Mon. 2008 Jul;54(7):432-44
references.pmid: 18570913
references.citation: Biometrika. 1950 Dec;37(3-4):256-66
references.pmid: 14801052
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1840-7
references.pmid: 20615891
references.citation: Int J Cancer. 2011 Aug 15;129(4):920-30
references.pmid: 20886596
references.citation: Cancer Lett. 2003 Apr 25;193(2):199-205
references.pmid: 12706878
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Dec;22(6):632-5
references.pmid: 16331559
references.citation: Cancer Lett. 2004 May 10;208(1):75-9
references.pmid: 15105048
references.citation: Semin Liver Dis. 2006 May;26(2):153-61
references.pmid: 16673293
references.citation: Front Biosci (Schol Ed). 2010 Jan 01;2:117-34
references.pmid: 20036934
references.citation: BMJ. 1998 Feb 7;316(7129):469; author reply 470-1
references.pmid: 9492685
references.citation: Oncol Lett. 2012 Apr 1;3(4):875-878
references.pmid: 22741010
references.citation: Carcinogenesis. 1999 Sep;20(9):1733-6
references.pmid: 10469618
references.citation: Carcinogenesis. 2008 Nov;29(11):2120-5
references.pmid: 18701437
references.citation: Liver Int. 2008 Feb;28(2):160-74
references.pmid: 18069974
references.citation: Mol Biol Rep. 2012 Feb;39(2):1639-47
references.pmid: 21607615